Search results for "chronic"

showing 10 items of 3309 documents

Chronic lateral epicondylitis of the elbow: A prospective study of low-energy shockwave therapy and low-energy shockwave therapy plus manual therapy …

2001

Abstract Rompe JD, Riedel C, Betz U, Fink C. Chronic lateral epicondylitis of the elbow: a prospective study of low-energy shockwave therapy and low-energy shockwave therapy plus manual therapy of the cervical spine. Arch Phys Med Rehabil 2001;82:578-82. Objective: To compare the effects of extracorporeal shockwave therapy (ESWT) alone with a combination of ESWT and manual therapy of the cervical spine in treating chronic tennis elbow. Design: Prospective, matched single-blind control trial. Setting: University hospital clinic. Patients: Thirty patients with unilateral chronic tennis elbow, an unsuccessful conservative therapy during the 6 months before referral, and clinical signs of cervi…

AdultMaleManipulation Spinalmedicine.medical_specialtymedicine.medical_treatmentUltrasonic TherapyElbowPhysical Therapy Sports Therapy and RehabilitationmedicineTennis elbowHumansSingle-Blind MethodProspective StudiesRange of Motion ArticularAgedPain MeasurementRehabilitationbusiness.industryEpicondylitisRehabilitationTennis ElbowMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureExtracorporeal shockwave therapyChronic DiseasePhysical therapyCervical VertebraeFemaleManual therapybusinessRange of motionCervical vertebraeArchives of physical medicine and rehabilitation
researchProduct

The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies

1999

Abstract Background/Aims: Cytotoxic T lymphocytes have been demonstrated in peripheral blood and liver tissue of patients with chronic hepatitis C virus infection, but their significance for viral clearance is unknown. Therefore, we analyzed hepatitis C virus-specific cytotoxic T lymphocyte precursor frequencies in chronic hepatitis C virus carriers during interferon-α treatment. Methods: Blood mononuclear cells or CD8+ T cells from HLA-A2 positive and negative patients and controls were analyzed in chromium-release assays using a panel of 18 synthetic peptides from the HCV core, E1 and NS4 antigens bearing HLA-A2 binding motifs. Specific cytotoxic T lymphocyte precursor frequencies were st…

AdultMaleMetabolic Clearance RateHepatitis C virusBiologymedicine.disease_causeAntiviral AgentsAntigenInterferonHLA-A2 AntigenmedicineHumansCytotoxic T cellHepatologyELISPOTInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyTreatment OutcomeCase-Control StudiesImmunologyFemaleViral loadCD8T-Lymphocytes Cytotoxicmedicine.drugJournal of Hepatology
researchProduct

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

2012

Prevalence and predictors of transmitted drug resistance (TDR), defined as the presence of at least one WHO surveillance drug resistance mutation (SDRM), were investigated in antiretroviral-naïve HIV-1-infected patients, with a genotypic resistance test (GRT) performed ≤6months before starting cART between 2000 and 2010. 3163 HIV-1 sequences were selected (69% subtype B). Overall, the prevalence of TDR was 12% (13.2% subtype B, 9% non-B). TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR. © 2012 The Authors. Clinical Microbiol…

AdultMaleMicrobiology (medical)CartDrugmedicine.medical_specialtyGenotypeAnti-HIV Agentsmedia_common.quotation_subjectHuman immunodeficiency virus (HIV)HIV InfectionsDrug resistancemedicine.disease_causeArticleEvolution Molecular03 medical and health sciencesrecent HIV infection0302 clinical medicineInternal medicineDrug Resistance ViralPrevalencemedicineHumansHIV Infection030212 general & internal medicinemedia_common0303 health scienceschronic HIV infection030306 microbiologybusiness.industryAntiretroviral therapy; Chronic HIV infection; Recent HIV infection; Resistance epidemiology; Transmitted resistance; Microbiology (medical); Infectious DiseasesAnti-HIV AgentGeneral MedicineMiddle Agedtransmitted resistanceVirologyAntiretroviral therapy3. Good healthAntiretroviral therapyInfectious DiseasesItalyHIV-1Genotypic resistanceFemalebusinessHumanresistance epidemiologyClinical Microbiology and Infection
researchProduct

Score to identify the severity of adult patients with influenza A (H1N1) 2009 virus infection at hospital admission

2012

The objective of this paper was to develop a prognostic index for severe complications among hospitalized patients with influenza A (H1N1) 2009 virus infection. We conducted a prospective observational cohort study of 618 inpatients with 2009 H1N1 virus infection admitted to 36 Spanish hospitals between July 2009 and February 2010. Risk factors evaluated included host-related factors and clinical data at admission. We developed a composite index of severe in-hospital complications (SIHC), which included: mortality, mechanical ventilation, septic shock, acute respiratory distress syndrome, and requirement for resuscitation maneuvers. Six factors were independently associated with SIHC: age >…

AdultMaleMicrobiology (medical)medicine.medical_specialtyChronic Obstructive Pulmonary DiseaseComorbiditymedicine.disease_causeSeverity of Illness IndexArticleBody Mass IndexSeasonal InfluenzaInfluenza A Virus H1N1 SubtypePregnancyRisk FactorsInternal medicineInfluenza HumanSeverity of illnessOdds RatiomedicineInfluenza A virusHumansIntensive Care Unit AdmissionProspective StudiesProspective cohort studyAgedRespiratory Distress SyndromeFramingham Risk ScoreSeptic shockbusiness.industryComputational BiologyGeneral MedicineOdds ratioMiddle AgedPrognosismedicine.diseaseRespiration ArtificialShock SepticInfluenzaSurgeryHospitalizationPneumoniaInfectious DiseasesROC CurveCase-Control StudiesMultivariate AnalysisFemaleInfluenza EpidemicbusinessCohort studyEuropean Journal of Clinical Microbiology & Infectious Diseases
researchProduct

Response-adjusted α-interferon therapy for chronic hepatitis C in HIV-infected patients

2000

Abstract In patients with chronic hepatitis C and HIV infection, responsiveness to the standard schedule of α-interferon (IFN) is unsatisfactory. To quantify the effectiveness of tailoring IFN dosage according to HCV viral load under treatment, we enrolled 41 patients (M/F 32/9) chronically coinfected by HCV and HIV with chronic liver disease. All were former i.v. drug addicts, with a mean age of 32±4 years, and had clinical and histological evidence of chronic hepatitis (10% with cirrhosis). The CDC stage was A1 in five, A2 in 14, A3 in eight, B2 in eight, B3 in three and C3 in three. Twenty four patients were on triple therapy with protease inhibitors, 11 were on two-drug anti-HIV regimen…

AdultMaleMicrobiology (medical)medicine.medical_specialtyCirrhosisSubstance-Related DisordersAlpha interferonHIV InfectionsHepacivirusChronic liver diseaseAntiviral AgentsGastroenterologyLiver diseaseInternal medicinemedicineHumansPharmacology (medical)Interferon alfabusiness.industryHIVInterferon-alphavirus diseasesGeneral MedicineHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseCD4 Lymphocyte CountTreatment OutcomeInfectious DiseasesImmunologyPatient ComplianceFemaleViral diseasebusinessViral loadmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Risk Factors and Outcome among a Large Patient Cohort with Community-Acquired Acute Hepatitis C in Italy

2006

Background The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated. Methods To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis C during 1999-2004. The patients were from 12 health care centers throughout the country, and they were followed up for a mean (+/- SD) period of 14+/-15.8 months. Biochemical liver tests were performed, and HCV RNA levels were monitored. Result…

AdultMaleMicrobiology (medical)medicine.medical_specialtyHepatitis C virusHepacivirus.medicine.disease_causeAsymptomaticMED/17 Malattie infettiveRisk FactorsInternal medicineEpidemiologyHumansMedicineRisk factorHepatitisbusiness.industryTransmission (medicine)Hepatitis CMiddle Agedmedicine.diseaseHepatitis CCommunity-Acquired InfectionsChronic infectionInfectious DiseasesItalyAcute DiseaseImmunologyFemalemedicine.symptombusinessClinical Infectious Diseases
researchProduct

Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study.

2019

<b><i>Background:</i></b> Onabotulinumtoxin A (OBT-A) is a treatment option for chronic migraine (CM), though the possible effect on central sensitization and allodynia is still unknown. <b><i>Aims:</i></b> The present study aimed to evaluate (1) the long-term outcome of allodynia in a group of CM treated with OBT-A (2) if the presence and severity of allodynia could predict the long-term effect of OBT-A (3) if the improvement of allodynia, could contribute to the clinical efficacy of OBT-A. <b><i>Methods:</i></b> This was an observational, open-label, cohort study conducted on 99 CM patients treated for 1 year and 44 p…

AdultMaleMigraine Disorders030204 cardiovascular system & hematologyAllodyniaCohort Studies03 medical and health sciences0302 clinical medicineChronic MigraineBotulinum toxinMedicineHumansBotulinum Toxins Type ADepression (differential diagnoses)Chronic migrainebusiness.industrymusculoskeletal neural and ocular physiologyCentral sensitizationMiddle Agedmedicine.diseaseBotulinum toxinSleep deprivationNociceptionAllodyniaTreatment OutcomeNeurologyMigraineNeuromuscular AgentsHyperalgesiaAnesthesiaAnxietyFemaleNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugEuropean neurology
researchProduct

Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis

2021

Development of primary liver cancer is a multistage process. Detailed understanding of sequential epigenetic alterations is largely missing. Here, we performed Infinium Human Methylation 450k BeadChips and RNA-Seq analyses for genome-wide methylome and transcriptome profiling of cirrhotic liver (n = 7), low- (n = 4) and high-grade (n = 9) dysplastic lesions, and early (n = 5) and progressed (n = 3) hepatocellular carcinomas (HCC) synchronously detected in 8 patients with HCC with chronic hepatitis B infection. Integrative analyses of epigenetically driven molecular changes were identified and validated in 2 independent cohorts comprising 887 HCCs. Mitochondrial DNA sequencing was further em…

AdultMaleMitochondrial DNACarcinoma HepatocellularCirrhosisMolecular biologyCarcinogenesisBiologyEpigenesis GeneticHepatitis B ChronicmedicineHumansEpigeneticsAgedHepatologyGene Expression ProfilingLiver NeoplasmsDNA NeoplasmGeneral MedicineMethylationDNA MethylationMiddle AgedHCCSmedicine.diseaseGene Expression Regulation NeoplasticOncologyApoptosisDNA methylationCancer researchEpigeneticsCalmodulin-Binding ProteinsFemaleLiver cancerLiver cancerResearch ArticleJCI Insight
researchProduct

Maintenance of Class III Trifurcated Molars Versus Implant Placement in Regenerated Extraction Sockets: Long-Term Results of 2 Cases

2011

Studies to date have reached differing conclusions regarding the long-term prognosis of teeth with class III furcation involvement. Replacement of such teeth with implants could be an alternative. This report compares the treatment outcomes of 2 cases with similar disease progression: 1 treated by implant therapy and 1 maintained with nonsurgical periodontal treatment. Two patients with advanced chronic periodontitis and class III furcation involvement of all molars were treated. Case 1 received a conservative periodontal and antibiotic treatment, followed by 15 years of maintenance. In case 2, the molars were extracted and replaced with implants, and the implants were observed for 7 years.…

AdultMaleMolarDentistryMandibleClass iiiFurcation InvolvementTooth LossMaxillaHumansMedicineTooth SocketDental ImplantsOrthodonticsSocket preservationbusiness.industryFurcation DefectsDental Implantation EndosseousDental Plaque IndexMandibleAlveolar Ridge AugmentationLong term resultsMolarSurvival AnalysisImplant placementTreatment OutcomeMaxillaChronic PeriodontitisTooth ExtractionGuided Tissue Regeneration PeriodontalDental ScalingFemaleOral SurgerybusinessFollow-Up StudiesJournal of Oral Implantology
researchProduct

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

2022

Background and ObjectivesSeveral studies have assessed risk factors associated with the severity of COVID-19 outcomes in people with multiple sclerosis (PwMS). The potential role of disease-modifying therapies (DMTs) and demographic and clinical factors on the risk of acquiring SARS-CoV-2 infection has not been evaluated so far. The objective of this study was to assess risk factors of contracting SARS-CoV-2 infection in PwMS by using data collected in the Italian MS Register (IMSR).MethodsA case-control (1:2) study was set up. Cases included PwMS with a confirmed diagnosis of COVID-19, and controls included PwMS without a confirmed diagnosis of COVID-19. Both groups were propensity score–m…

AdultMaleMultiple SclerosisTime Factors41Dimethyl FumarateSex FactorRelapsing-RemittingSeverity of Illness IndexArticleImmunosuppressive AgentSex FactorsMultiple Sclerosis Relapsing-RemittingRisk FactorsMultiple SclerosiOdds RatioHumansAge Factor36053g COVID-19Fingolimod HydrochlorideSARS-CoV-2NatalizumabRisk FactorAge FactorsCOVID-19Glatiramer AcetateInterferon-betaMiddle AgedMultiple Sclerosis Chronic Progressive323Chronic ProgressiveNeurologyItalyCase-Control StudiesAdult; Age Factors; COVID-19; Case-Control Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time FactorsFemaleNeurology (clinical)Case-Control StudieImmunosuppressive AgentsHuman
researchProduct